RE
REGN
Quarter ended Mar 31, 2023 · FY2023 Q1

Regeneron Pharmaceuticals (REGN) Revenue — Quarter Ended Mar 31, 2023

Revenue for the quarter declined compared to the immediately preceding quarter. However, revenue increased relative to the same quarter one year earlier.

Key takeaway

Quarter ended Mar 31, 2023 · FY2023 Q1

Revenue for the quarter declined compared to the immediately preceding quarter. However, revenue increased relative to the same quarter one year earlier.

Financial snapshot

Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.

Quarter revenue

$3.2B

Revenue reported for this quarter.

Quarter-over-quarter

-7.4%

Change from the immediately preceding quarter.

Year-over-year

+6.6%

Change from the comparable year-ago quarter.

Trailing four quarters

$12.4B

Sum of the latest four reported quarters.

Quarterly revenue trend

The latest four reported quarters with year-over-year comparisons.

Period endedRevenueYear-over-year change
Jun 30, 2022$2.9B-44.4%
Sep 30, 2022$2.9B-15.0%
Dec 31, 2022$3.4B-31.0%
Mar 31, 2023$3.2B+6.6%

Revenue performance

The reported revenue direction is downward from the prior quarter. The sequential decline reflects a reversal from the growth seen in the trailing twelve months.

Quarterly comparison

Compared to the immediately preceding quarter, revenue decreased. In contrast, compared to the same quarter one year earlier, revenue increased.

What to watch

Monitor whether the sequential revenue decline persists in future quarters.